4461 DKS
- 3830
- -15-0.39%
DKS News
DKS: Summary of financial results for the 2nd quarter (interim period) for the fiscal year ending March 31, 2025 [Japanese GAAP] (consolidated)
DKS: Notice regarding revisions to consolidated earnings forecasts for the 2nd quarter and full-year consolidated earnings forecasts for the fiscal year ending March 31, 2025, and revisions to dividend forecasts
DKS: 1st quarter financial results for the March 2025 period (consolidated) based on Japanese standards.
DKS: Interim report
DKS: Confirmation letter
DKS: Securities Report - 160th term (April 1, 2023 to March 31, 2024)
DKS: Summary of Financial Results for the Fiscal Year Ending March 31, 2024 [Japanese GAAP] (Consolidated)
Dai-ichi Kogyo Pharmaceutical: Notice regarding revisions to the full-year consolidated earnings forecast for the fiscal year ending March 31, 2024 and dividends (dividends increase) from surplus
Dai-ichi Kogyo Pharmaceutical: Quarterly Report - 160th Term 3rd Quarter (2023/10/01 - 2023/12/31)
Daiichi Kogyo Pharmaceutical: Confirmation
DKS: Summary of Financial Results for the 3rd Quarter Ending March 31, 2024 [Japanese GAAP] (Consolidated)
DKS: Quarterly Report - 160th Second Quarter (2023/07/01 - 2023/09/30)
DKS: Confirmation letter
DKS: Notice regarding differences between second quarter consolidated earnings forecasts and actual results and revisions to full-year consolidated earnings forecasts
DKS: Summary of Financial Results for the 2nd Quarter Ending March 2024 [Japanese GAAP] (Consolidated)
DKS: Confirmation letter
DKS: Quarterly Report - First Quarter 160 (2023/04/01 - 2023/06/30)
DKS: Summary of Financial Results for the First Quarter of the Fiscal Year Ending March 31, 2024 [Japanese GAAP] (Consolidated)
DKS: Extraordinary Report
DKS: Securities Report - 159th Period (2022/04/01 - 2023/03/31)
Analysis
Price Target
No Data
No Data